Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maintenance selinexor versus placebo after platinum-taxane chemotherapy for advanced or recurrent endometrial cancer
MOH_2019-01-29_004920Phase 3Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) comparing Selinexor maintenance with Placebo maintenance (2 arms). Started Jan 2019; status: completed.
02
Drugs
selinexor
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2019-01-29_004920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-29_004920.